Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cord Blood IgE Levels Tied To Allergy, Asthma Rates

By LabMedica International staff writers
Posted on 22 Aug 2022

The rising prevalence of allergic diseases worldwide represents an important health problem. More...

Early identification of children at high risk of allergic diseases could be helpful for physicians to recommend preventive measures and apply early interventions.

Cord blood immunoglobulin E (IgE) has been considered as a potential marker for years due to its predictability for allergic diseases, but the results are controversial. Several studies have reported that elevated cord blood IgE may predict allergic diseases and/or allergic sensitization in childhood, whereas other studies failed to find it as a good predictor.

Immunologists at the Chang Gung Memorial Hospital (Taoyuan, Taiwan) included 566 children (321 boys; mean age, 6.5 ± 0.4 years) in a prospective population-based cohort study designed to longitudinally investigate the effects of early-life environmental exposures and genetic predisposition on childhood allergic outcomes. Blood samples were drawn for subsequent measurement of serum total and allergen-specific IgE. Measurements of nitric oxide (FeNO) and pulmonary function were performed in standard procedures.

Serum total IgE was determined by ImmunoCAP (Phadia, Uppsala, Sweden). Allergic sensitization was defined as a positive Phadia Phadiatop Infant test result (≧0.35 PAU/L), detecting allergen-specific IgE against a mix of common inhalant and food allergens. Serum levels of allergen-specific IgE were measured using an automated microfluidic-based multiplexed immunoassay system, the BioIC Allergen-specific IgE Detection Kit- AD40 Panel; Agnitio Science and Technology, Hsinchu, Taiwan). FeNO measurement was performed by chemiluminescence analyzer (CLD 88sp NO analyzer, Ecomedics, Duernten, Switzerland).

The investigators reported that cord blood IgE levels were significantly associated with FeNO levels and serum total IgE levels. Cord blood IgE levels were positively associated with allergic sensitization (adjusted odds ratio [AOR] = 2.22). Specifically, they found significant associations between elevated levels of IgE in cord blood and higher likelihoods for sensitization to house dust mites (Dermatophagoides pteronyssinus and D. farina), dog dander, egg yolk, garlic and baker’s yeast.

Subjects with cord blood IgE ≥0.24 kU/L (the optimal cutoff) were significantly associated with an increased risk of allergic sensitization (AOR = 2.63,) and asthma (AOR = 2.35) than those with cord blood IgE <0.24 kU/L. Subjects with cord blood IgE ≥0.24 kU/L had significantly higher FeNO levels than those with cord blood IgE <0.24 kU/L. There were no significant associations between cord blood IgE levels and pulmonary function parameters.

The authors concluded that that cord blood IgE ≥0.24 kU/L predicts allergic sensitization, FeNO elevation, and asthma among Asian schoolchildren. Specifically, cord blood IgE levels ≥0.24 kU/L was associated with a 2.6-fold increased risk of allergic sensitization, particularly sensitization to mites, animals, and foods, at six years of age. This study suggests that cord blood IgE levels would be useful for early identification of newborns at risk of subsequent allergic sensitization and allergic airway inflammation at school age. The study was published on August 1, 2022 in the journal Pediatric Allergy and Immunology.

Related Links:

Chang Gung Memorial Hospital
Phadia
Agnitio Science and Technology
Ecomedics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.